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Abstract: Several phosphorus-substituted N-acylated cyanoaziridines 2 and N-carbamoylated
cyanoziridines 5 were prepared in good to high yields. N-Acylated cyanoaziridines 2 were used, after
ring expansion, in an efficient synthesis of oxazoline derivative 3a and in a completely regio-controlled
reaction in the presence of NaI. Conversely, N-carbamoyl cyanoaziridines 5 reacted with NaI to
obtain a regioisomeric mixture of 2-aminocyanooxazolines 7. Mild acidic conditions can be used for
the isomerization of N-thiocarbamoyl cyanoaziridine 6a into a 2-aminocyanothiazoline derivative 8a
by using BF3·OEt2 as a Lewis acid. Likewise, a one pot reaction of NH-cyanoaziridines 1 with iso-
cyanates obtained 2-iminocyanooxazolidines 9 regioselectively. This synthetic methodology involves
the addition of isocyanates to starting cyanoaziridines to obtain N-carbamoyl cyanoaziridines 5,
which after the ring opening, reacts with a second equivalent of isocyanate to give the final 2-imino
cyanooxazolidines 9. In addition, the cytotoxic effect on the cell lines derived from human lung
adenocarcinoma (A549) was also screened. 2-Iminooxazolidines 9 exhibited moderate activity against
the A549 cell line in vitro. Furthermore, a selectivity towards cancer cells (A549) over non-malignant
cells (MCR-5) was detected.
Keywords: phosphorus substituted cyanoaziridines; 4-cyanooxazolines; 2-aminocyanooxazolines;
2-iminocyanooxazolidines; 2-aminocyanothiazolines; antiproliferative effect
1. Introduction
DNA-modifying agents are a significant class of pharmaceuticals used in conventional
chemotherapy. Aziridine-based cytostatic compounds, acting as powerful alkylating
agents, have an inherent in vivo potency due to their ability to act as DNA cross-linking
agents via the ring opening of aziridine [1]. Mitomycin C and many variants of this
natural product have been well characterized for their anti-tumor activity based on the
nucleophilic ring opening of the three-membered nitrogen heterocycle, leading to the
alkylation of DNA [2]. Mitomycin C is a conventional DNA cross-linking agent that uses
the reductive activation of the aziridine moiety to form lethal DNA–DNA cross-links,
as well as, more often, mono-alkylated DNA products [3]. Founded on this knowledge,
during the early 1970s Bicker [4,5] developed a variety of 2-cyanoaziridine derivatives as
potential carcinostatic agents. For instance, 2-cyanoaziridine-1-carboxamide (Ia, Figure 1)
was active against a PIE 2-3 sarcoma in Wistar rats, and it had a low toxicity. However,
it showed weak antitumor activity in cell cultures. The fact that it increased rather than
decreased the number of leukocytes was especially interesting [5]. However, in contrast
to the initial findings, these cyanoaziridines showed no alkylating activity in vitro or
in vivo [4]. These results suggest that the cyano group reduces the reactivity required for
the alkylation of DNA bases and that they may selectively react with sulfur moieties in
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biological thiols such as cysteine, depleting the stores of cysteine and glutathione and
subsequently allowing the accumulation of cellular reactive oxygen species (ROS) [6–8].
Preclinical studies have evaluated the antitumor activity and the mechanism of action of
cyanoaziridine AMP423 (Ib, Figure 1) [6]. Other cyanoaziridines such as ciamexon (II) and
azimexon (III, Figure 1) [9] were screened for antitumor activity, with brief clinical trials
in the late 1980s. Both ciamexon (II) and azimexon (III) displayed antitumor activity in a
variety of animal models including the Lewis lung tumor, the Madison lung carcinoma,
Meth A sarcoma, and AKR leukemia, but they had no direct antitumor activity in vitro
according to Bicker [5] and they are no longer used. The iminopyrrolidone compound
imexon (IV), produced by the cyclization of 2-cyanoaziridine-1-carboxamide (Ia) in the
presence of hydroxide ions [10,11], is an anti-neoplastic agent that increases oxidative stress
in the target and it has been extensively used due to its selective growth inhibitory effect
against multiple myeloma [12–14]. This small-molecule chemotherapeutic agent is widely
used to treat advanced cancers of the breast, lung, and prostate. The biological activity of
imexon is narrowly associated with cyanoaziridines since imexon solutions in water slowly
revert to Ia. In 1999, Remers et al. [15] reported the synthesis of a series of 2-cyanoaziridine-
1-carboxamides that were active against a variety of solid and hematological tumor cells
in culture. The N-Phenyl derivative (Ic, R = Ph, Figure 1) tested in human tumor cells
was found to be related to imexon in activity. More recently, our research group reported
the preparation of phosphorus substituted cyanoaziridines and evaluated them by testing
their antiproliferative activities against different human cancer cell lines. For instance, the
phosphonate-derived cyanoaziridine V showed in vitro cytotoxicity against the A549 cell
line with an IC50 value of 1.5 ± 0.84 µM [16].
Figure 1. Representative examples of 2-cyanoaziridines as antitumor drugs.
Furthermore, the ring-expansion of aziridines with isocyanates has been revealed to
be a useful pathway for the synthesis of a variety of five-membered nitrogen-containing
compounds. For instance, KI [17], NaI [18–20], NiI2 [21], Pd-catalyzed [22–24] reactions of
aziridines with isocyanates, or even in the absence of catalysts [25], have been described.
All these reactions yielded imidazolidin-2-ones or oxazolidin-2-imines compounds which
generate great interest in medicinal and pharmaceutical chemistry since they represent
classes of heterocyclic compounds with a broad variety of biological activities [26,27]. In
the last few years we have been involved in the chemistry related to phosphorylated
2H-azirines for the preparation of α- or β-aminophosphonic acid derivatives [28–30],
pyrroles [31,32], oxazoles [33], 1H-benzo[d]azepines [31], or hybrid molecules such as
azirino [2,1-b]benzo[e][1,3]oxazines [34], among others. Additionally, organophosphorus
derivatives are fascinating compounds from a biological point of view, due to the fact
that these substituents may regulate relevant biological functions modifying the reactivity
of heterocyclic systems [35]. Recently, we have revealed a diastereoselective method for
the preparation of phosphorus substituted cyanoaziridines by means of the nucleophilic
addition of TMSCN as a cyanide source to the C–N double bond of 2H-azirines [16]. Fol-
lowing our earlier studies on the preparation of phosphorylated cyanoaziridines, here we
wish to report the synthesis of structurally new phosphorus substituted N-(thio)carbamoyl
cyanoaziridines by the coupling of unactivated cyanoaziridines with iso(thio)cyanates.
Moreover, the ring expansion into 2-aminocyanooxazolines, 2-aminocyanothiazolines, or
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2-iminocyanooxazolidines under nucleophilic or acidic conditions is also explored. We
also focus on their biological activity and highlight the antiproliferative effect of all these
new heterocycles on A549 human lung adenocarcinoma cells.
2. Results
2.1. Chemistry
As a continuation of the studies on the synthesis and applications of activated
aziridines through the N-functionalization of unactivated cyanoaziridines [16], and taking
into account that N-acylaziridines are very important synthons in the development of new
ring opening aziridine reactions, we initially studied the N-acylation reaction of cyanoaziri-
dine phosphine oxides 1a (R = Ph, R1 = Me) and 1b (R = Ph, R1 = Et), and phosphonate 1c
(R = OEt, R1 = Me). Thus, the N-acylation of cyanoaziridines 1a–c using 3,5-dinitrobenzoyl
chloride in the presence of a base, such as Et3N, and methylene chloride as the solvent,
obtained N-acylated cyanoziridines 2a–c in good chemical yields (80–93%) (Scheme 1).
Scheme 1. Synthesis of N-acylated cyanoaziridines phosphine oxides and phosphonates 2.
We next studied the isomerization reaction (Heine reaction) of the corresponding
synthesized phosphorus-containing N-acylated cyanoaziridines 2. For this purpose, we
chose nucleophilic conditions [36–39], and the isomerization of benzoyl aziridine 2a was
accomplished by the use of the sodium iodide method. Indeed, when phosphorus substi-
tuted N-acylated cyanoaziridine 2a reacted with 0.2 equivalents of NaI in THF at 60 ◦C
in a sealed-tube, 4-cyanooxazoline derived from phosphine oxide 3a was obtained in a
regioselective way in a 65% yield (Scheme 2).
Scheme 2. Ring expansion of cyanoaziridine 2a to oxazoline 3a.
Even though the iodide anion may attack both the aziridine carbon atoms, and the
regioselectivity will be determined by the stereoelectronic nature of the substituents, several
reports in the literature describe the aziridine ring opening through the less hindered
position [40–42]. Bear in mind that the most reasonable mechanism may consider a first step
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where the iodide anion would attack at the C2 aziridine carbon that was substituted less in
a regiospecific manner, followed by the aziridine ring opening obtaining intermediate 4.
The iodide displacement in the former intermediate may afford phosphorus substituted
4-cyanooxazoline 3a (Scheme 2).
Unactivated NH-aziridines are very stable compounds in basic conditions and may
easily react with electrophiles. Next, we explored the N-functionalization of unactivated
cyanoaziridines derived from phosphine oxides and phosphonates 1 with aromatic and
aliphatic isocyanates for the preparation of functionalized N-aryl or N-alkylcarbamoyl
cyanoaziridines.
Therefore, the reaction of cyanoaziridines 1 with isocyanates was assessed. Thus, as
outlined in Table 1, in an initial experiment the addition of phenyl isocyanate to cyanoaziri-
dine phosphine oxide 1a (R = Ph, R1 = Me) was readily achieved in dichloromethane at
room temperature. A total of 1.2 equivalents of the isocyanate component were used in
order to ensure a full conversion. Under these reaction conditions, the corresponding
phosphorus substituted N-phenylcarbamoyl cyanoaziridine 5a (R = R2 = Ph, R1 = Me) was
obtained in a 63% yield (Table 1, entry 1).
Table 1. Phosphorus substituted N-aryl or N-alkylcarbamoyl cyanoaziridines 5 obtained.
Entry Compound R R1 R2 Yield (%) a
1 5a Ph Me Ph 63
2 5a Ph Me Ph 71 b
3 5b OEt Me Ph 98
4 5c Ph Me p-MeC6H4 82
5 5d OEt Me p-MeC6H4 80
6 5e Ph Et p-MeC6H4SO2 86
7 5f OEt Me p-MeC6H4SO2 79
8 5g Ph Me Et 86 c
9 5h OEt Me Et 59 c
10 5i Ph Me tBu 73 c
11 5j OEt Me tBu 75 c
11 5k Ph Et tBu 64 c
a Isolated yield of purified compounds 5. b Reaction conditions: isocyanate (3 eq) and Sc (OTf)3 (20% mol) in
CH2Cl2 at 0 ◦C. c Reaction conditions: isocyanate (2 eq) and ZnCl2 (1.25 eq) in CH2Cl2 at 25 ◦C.
Some examples in the literature describe the use of Lewis acids as transition metal
catalysts involving reactions of aziridines and isocyanates [22,43,44]. Hence, we explored
the reaction of phenyl isocianate with cyanoaziridine 1a in the presence of a Lewis acid.
Better yields and reduced reaction times were observed for the synthesis of 5a using
catalytic ammounts of Sc (OTf)3 (20%) (see Table 1, entry 2). In the same way, phosphate-
derived cyanoziridine 1c (R = OEt, R1 = Me) reacted with phenyl isocyanate in CH2Cl2 at
room temperature, without a catalyst, to give N-functionalized cyanoaziridine 5b (R = OEt,
R1 = Me, R2 = Ph) in very good chemical yields (Table 1, entry 3).
As illustrated in Table 1, this synthetic methodology is tolerant of a variety of functional-
ized isocyanates with varying substitutions. For instance, cyanoaziridines 1a and 1c reacted
with p-tolyl isocyanate (R2 = p-MeC6H4) to give N-p-tolylcarbamoyl cyanoaziridines 5c and 5d,
respectively (Table 1, entries 4 and 5). Likewise, under the same reaction conditions, cyanoaziri-
dine 1a reacted with p-toluenesulfonyl isocyanate. The crude product 5 (R = Ph, R1 = Me,
R2 = p-MeC6H4SO2) was observed by 1H and 31P NMR; however, any further purifica-
tion step through crystallization or chromatography produced the hydrolyzed starting
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cyanoaziridine 1a. Conversely, N-p-toluenesulfonylcarbamoyl cyanoaziridines 5e (R = Ph,
R1 = Et, R2 = p-MeC6H4SO2, Table 1, entry 6) and 5f (R = OEt, R1 = Me, R2 = p-MeC6H4SO2,
Table 1, entry 7) were obtained in 86 and 79% yields, respectively, by means of the treatment
of the corresponding cyanoaziridines 1b and 1c with p-toluenesulfonyl isocyanate.
This process was extended to the reactivity of phosphorus substituted cyanoziridines 1
with alkyl isocyanates, such as ethyl and tert-butyl isocyanate. The same reaction conditions
used for the aromatic isocyanates were employed for the reaction of 1a with ethyl isocyanate.
Nevertheless, no progress was observed on the formation of compound 5g, and the starting
cyanoaziridine 1a was recovered instead. The Lewis acid activation of the aziridine ring in
the reaction of 1a with ethyl isocyanate led to the formation of the expected compound 5g.
Thus, the presence of 20% mol of Sc (OTf)3 as a Lewis acid, as described before for the
synthesis of 5a, gave only a 50% conversion of N-ethylcarbamoyl cyanoaziridine 5g (R = Ph,
R1 = Me, R2 = Et) after 24 h of the reaction. However, when two equivalents of ethyl
isocyanate reacted with cyanoaziridine 1a in the presence of 1.25 equivalents of ZnCl2
in CH2Cl2 and at room temperature, N-functionalized cyanoaziridine 5g was obtained
with a 86% chemical yield (Table 1, entry 8). Similarly, the addition of ethyl isocyanate to
phosphonate-derived cyanoaziridine 1c, using ZnCl2 as a Lewis acid, led to the formation
of N-functionalized aziridine 5h (R = OEt, R1 = Me, R2 = Et; Table 1, entry 9). In addition,
the synthesis of N-tert-butylcarbamoyl cyanoaziridines 5i–k (Table 1, entries 10–12) was
achieved in moderate yields, using tert-butyl isocyanate as an electrophile and ZnCl2 as a
Lewis acid.
The synthetic procedure for the preparation of N-aryl or N-alkylcarbamoyl cyanoaziridines 5
could be widened to the addition of isothiocyanates to cyanoaziridines 1 (Table 2). Under the
same reaction conditions used for the preparation of derivatives 5, phenyl isothiocyanate, p-
methoxyphenyl isothiocyanate, or p-nitrophenyl isothiocyanate did not react with cyanoaziridine 1a
to yield compounds 6. Moreover, the use of different bases, such as Et3N, pyridine, NaH, or
Cs2CO3, as well as Lewis acids such as ZnCl2 or Sc (OTf)3, gave similar results: the formation
of N-functionalized cyanoaziridines 6 was not observed and the starting compound 1a was
recovered instead.
Table 2. Phosphorus substituted N-ethoxycarbonylthiocarbamoyl cyanoaziridines 6 obtained.
Entry Compound R R1 Method a Yield (%) b
1 6a Ph Me A 71
2 6a Ph Me B 80
3 6b Ph Et A 85
4 6c OEt Me B 86
a Reaction conditions. Method A: isothiocyanate (1.2 eq) in CH2Cl2 at −30 ◦C. Method B: isothiocyanate (1.2 eq)
in CH2Cl2 at 25 ◦C. b Isolated yield of purified compounds 6.
In order to achieve the synthesis of new derivatives 6, we decided to use a more
reactive isothiocyanate derivative. Thus, functionalized isothiocyanates with an electron-
withdrawing group, such as ethoxycarbonyl isothiocyanate, reacted with cyanoaziridines
derived from phosphine oxide 1a and 1b in CH2Cl2 at −30 ◦C (Method A). Under these
reaction conditions, compounds 6a and 6b were attained in 71% and 85% chemical yields, re-
spectively (Table 2, entries 1 and 3). Increasing the reaction temperature to 25 ◦C (Method B)
gave better yields and the N-functionalized cyanoaziridine 6a was obtained in an 80%
yield (Table 2, entry 2). Similarly, phosphonate-derived cyanoaziridine 1c reacted with
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ethoxycarbonyl isothiocyanate in CH2Cl2 at room temperature to afford N-thiocarbamoyl
cyanoaziridine 6c (R = OEt, R1 = Me) in good yields (Table 2, entry 4).
Continuing with our interest in the synthesis of new 5-membered nitrogen contain-
ing heterocyclic compounds, we then explored the ring expansion of some N-carbamoyl
cyanoaziridine derivatives 5. To this end, and using the same reaction conditions as in the
case of N-acyl cyanoaziridine 2, N-arylcarbamoyl cyanoaziridines derived from phosphine
oxide 5a (R = R2 = Ph) and 5c (R = Ph, R2 = p-MeC6H4) reacted with 0.2 equivalents of NaI
at 60 ◦C in THF, allowing the preparation of oxazolines 7a and 7c, respectively (Table 3,
entries 1 and 3). As evidenced by 1H and 31P NMR, oxazolines 7 were obtained as a mixture
of two regioisomers 7 and 7′, in a 66:34 ratio for 7a, while a 65:35 ratio was observed for
oxazoline 7c. Oxazolines 7 were purified by flash-column chromatography, allowing the
isolation of a single isomer, corresponding to the minor one in the case of 7a+7′a. However,
in the case of regioisomeric oxazolines 7c+7′c, the separation of both regioisomers was not
possible, and the same 65:35 ratio was obtained after purification by flash-column chro-
matography. We also tested the ring expansion of N-arylcarbamoyl cyanoaziridines derived
from phosphonate 5b and 5d under the optimal conditions. For instance, phosphonate-
derived oxazolines 7b (R = OEt, R2 = Ph) and 7d (R = OEt, R2 = p-MeC6H4) were obtained
as regioisomeric mixtures after treatment with 5b and 5d, respectively, with 0.2 equivalents
of NaI at 60 ◦C in THF (Table 3, entries 2 and 4). Conversely, the NaI catalyzed ring expan-
sion of N-alkylcarbamoyl cyanoaziridines 5g (R = Ph, R1 = Me, R2 = Et) and 5k (R = Ph,
R1 = Et, R2 = tBu) to the corresponding oxazolines was not observed, and N-functionalized
cyanoaziridines 5g and 5k were recovered instead.
Table 3. Regioisomeric phosphorus substituted oxazolines derivatives 7 obtained.
Entry Compound R R2 Yield (%) a Ratio b
1 7a + 7′a Ph Ph 45 66:34
2 7b + 7′b OEt Ph 69 64:36
3 7c + 7′c Ph p-MeC6H4 75 65:35
4 7d + 7′d OEt p-MeC6H4 54 66:34
a Isolated yield of purified oxazolines 7. b Regioisomeric ratio was determined by crude 31P NMR spectra.
A rational mechanism for the formation of oxazoline derivatives 7 can be explained via
the initial aziridine ring opening in 5 by an indiscriminate iodide attack to either aziridine
carbons C2 or C3. Subsequent ring closure by iodide displacement would afford a mixture
of regioisomeric oxazolines 7 and 7′. It seems reasonable to assume that the role of the
stereoelectronic nature of N-substituents on the aziridine ring may affect the selectivity
of these cyanooxazoline derivatives. Only one regioisomer was formed in the reaction of
N-acylcyanoaziridine 2a in the presence of NaI, suggesting the possibility that the N-acyl
substituent could exert a neighboring group participation effect, although this does not
take place in the case of the N-arylcarbamoyl group.
Several attempts have been carried out in the synthesis of thiazoline derivatives
starting from aziridines. It is known that 2-substituted oxazolines or imidazolines can
be prepared by the ring expansion of aziridines or benzoylated imidoyl aziridines, re-
spectively [41,45,46], through the Heine reaction. For instance, aziridines undergo ring
expansion reactions into oxazolines with Lewis acids [47] and, recently, based on these
results, Tepe et al. [48] have described the isomerization of aziridines to oxazolines us-
ing BF3·OEt2. For this reason, we explored the ring expansion of functionalized N-
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thiocarbamoyl cyanoaziridine 6a. Initially, we studied the aziridine ring opening un-
der thermal conditions. Thus, N-thiocarbamoyl cyanoaziridine derived from phosphine
oxide 6a was heated in refluxing CHCl3. Under these conditions, no reaction was observed,
and the unreacted starting substrate was recovered. Next, the Heine-type reaction was also
studied under nucleophilic conditions by using NaI at 60 ◦C in THF, and as in the previous
case, no satisfactory results were attained.
Likewise, the conversion of aziridine to thiazoline under mild acidic conditions was
examined. N-Functionalized cyanoaziridine 6a was treated with both Brønsted acids, such
as p-toluenesulfonic acid (PTSA), and Lewis acids, such as ZnCl2 or BF3·OEt2. Only the
use of BF3·OEt2 gave satisfactory results. Hence, when N-thiocarbamoyl cyanoaziridine 6a
reacted in the presence of 5 equivalents of BF3·OEt2 at −70 ◦C in THF, the formation
of 2-aminothiazoline phosphine oxide 8a was detected (Scheme 3). Spectroscopic data
confirmed the isomerization of aziridine 6a into 2-aminothiazoline 8a. While the 1H NMR
spectrum of 6a showed a signal for the methyl group at δH = 2.0 ppm and the methine
hydrogen resonated at δH = 3.8 ppm as a well-resolved doublet (2JPH = 20 Hz), in 2-
aminothiazolidine 8a these signals appeared at lower fields: δH = 2.11 and 4.58 ppm as a
singlet and a well-resolved doublet (2JPH = 12.8 Hz), respectively.
Scheme 3. Stereospecific ring expansion of N-thiocarbamoyl cyanoaziridine 6a to 2-aminothiazoline 8a.
Since it was not conclusively irrefutable that 1H and 13C NMR were assigned to
the regio- and stereochemistry of compound 8a, the X-ray diffraction analysis not only
established the regiochemistry of compound 8a, but also the syn-relationship between
the cyano group at the C3 position and the phosphorus moiety at the C2 position of
8a (Figure 2).
A reasonable mechanism that would explain the formation of 8a is exemplified in
Scheme 3. First, BF3·OEt2 would coordinate with the sulfur atom of cyanoaziridine 6a,
thus assisting the ring opening reaction through the N–C3 bond, with the concomitant
generation of the most stable carbocation. The cationic intermediate coming from the
aziridine with an E-stereochemistry would isomerize, and the ring closure would lead to
2-aminothiazoline 8a as the only regio- and stereoisomer.
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Figure 2. ORTEP diagram of compound 8a.
Continuing with our interest in the synthesis of new nitrogen-containing heterocyclic
compounds, finally we examined the one pot reaction of cyanoaziridines 1 with isocyanates
in order to obtain new oxazoline derivatives.
For this purpose, phosphorus subtituted cyanoaziridine 1b (R = Ph, R1 = Et) reacted
with phenyl isocyanate in acetonitrile at 60 ◦C, leading to the formation of iminooxa-
zolidine 9a in low yields (Scheme 4). The addition of 2 equivalents of isocyanate led
to 9a in moderate yields (45%), whereas, when the reaction was examined in the pres-
ence of KI (30% mol) using 2 equivalents of phenyl isocyanate in acetonitrile at 60 ◦C,
the corresponding iminooxazolidine 9a was obtained in a 62% yield (Scheme 4, Table 4,
entry 1). Similarly, cyanoaziridine 1a (R = Ph, R1 = Me) reacted with p-tolenesulfonyl
isocyanate using the same reaction conditions, providing a 55% yield of iminooxazolidine
9b (Scheme 4, Table 4, entry 2). This synthetic methodology was extended to the use of
cyanoaziridines derived from phosphonate. Thus, 1c (R = OEt, R1 = Me) reacted with
phenyl isocyanate in the presence of KI in acetonitrile at 60 ◦C to give iminooxazolidine 9c
(Scheme 4, Table 4, entry 3).
Scheme 4. Synthesis of iminooxazolidines 9 through one pot reaction from cyanoaziridines 1.
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Table 4. Preparation of iminoxazolidines 9.
Entry Compound R R1 R2 Yield (%) a
1 9a Ph Et Ph 62
2 9b Ph Me p-MeC6H4 55
3 9d OEt Me Ph 79
a Isolated yield of purified compounds 9.
A reliable mechanism for the formation of 9 would indicate the addition of an
equivalent of isocyanate to cyanoaziridine 1 to obtain the corresponding N-carbamoyl
cyanoaziridines 5 (Scheme 4). Then, the regiospecific attack of the iodide ion at the less
substitute carbon atom (C2) in aziridines 5 would lead to the ring opening, affording
intermediates 10. The former intermediates would attack the carbon center of a second
isocyanate equivalent followed by the ring closure to yield iminooxazolidines 9.
2.2. Biological Results
The in vitro cytotoxicity of our novel N-functionalized cyanoaziridines 2, 5 and 6
derived from phosphine oxide (R = Ph) and phosphonate (R = OEt), as well as the five-
membered nitrogen-containing heterocycles 3a, 7, 8a and 9 was evaluated by testing their
antiproliferative activities against the human cancer cell line A549 (carcinomic human
alveolar basal epithelial cells). In order to evaluate the growth inhibition, a cell counting kit
(CCK-8) assay was applied. Cell proliferation inhibitory activities as IC50 values for all the
synthesized compounds and chemotherapeutic doxorubicin (DOX) are displayed in Table 5.
Likewise, healthy lung cells, such as MRC-5 non-malignant lung fibroblasts were tested to
study the selective cytotoxicity [49]. We first examined the nitrogen-substitution effect of the
corresponding cyanoaziridines into their cytotoxicity against A549 cell lines. The best result
was observed for N-acylated cyanoaziridine 2a derived from phosphine oxide with an IC50
value of 22.9 ± 1.9 µM (Table 5, entry 2). However, N-acylated cyanoaziridines derived from
phosphine oxide 2b and phosphonate 2c (Table 5, entries 3 and 4), as well as N-carbamoyl
cyanoaziridines 5a–k (Table 5, entries 6–16) and N-thiocarbamoyl cyanoaziridines 6a–c
(Table 5, entries 17–19) did not exhibit any toxicity toward the A549 cell line.
Table 5. Antiproliferative activity of synthesized N-functionalized cyanoaziridines 2, 5, and 6 and 5-membered nitrogen-
containing heterocycles 3a, 7, 8a and 9.
Entry Comp. R R1 R2
Cytotoxicity IC50 (µM) a
Lung A549 MRC-5
1 0.48 ± 0.017 [50] >50 [51]
2 2a Ph Me – 22.9 ± 1.9 >50
3 2b Ph Et – >50 >50
4 2c OEt Me – >50 >50
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Table 5. Cont.
Entry Comp. R R1 R2
Cytotoxicity IC50 (µM) a
Lung A549 MRC-5
5 3a Ph Me – 19.7± 2.8 >50
6 5a Ph Me Ph >50 >50
7 5b OEt Me Ph >50 >50
8 5c Ph Me p-MeC6H4 >50 >50
9 5d OEt Me p-MeC6H4 >50 >50
10 5e Ph Et p-MeC6H4SO2
>50 >50
11 5f OEt Me p-MeC6H4SO2
>50 >50
12 5g Ph Me Et >50 >50
13 5h OEt Me Et >50 >50
14 5i Ph Me tBu >50 >50
15 5j OEt Me tBu >50 >50
16 5k Ph Et tBu >50 >50
17 6a Ph Me – >50 >50
18 6b Ph Et – >50 >50
19 6c OEt Me – >50 >50
20 7a + 7′a Ph Me Ph >50 >50
21 7b + 7′b OEt Me Ph >50 >50
22 7c + 7′c Ph Me p-MeC6H4 >50 >50
23 7d + 7′d OEt Me p-MeC6H4 >50 >50
24 8a Ph Me – >50 >50
25 9a Ph Et Ph 16.4 ± 1.5 >50
26 9b Ph Me p-MeC6H4 14.8 ± 1.2 >50
27 9c OEt Me Ph 6.2 ± 0.7 >50
a The cytotoxicity IC50 values listed are the concentrations corresponding to 50% growth inhibition.
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Concerning the new 5-membered nitrogen-containing heterocycles derived from the
ring expansion of N-functionalized cyanoaziridines against the A549 cell line in vitro,
oxazoline derivative 3a showed a IC50 value of 19.7 ± 2.8 µM (Table 5, entry 5). Conversely,
neither the regioisomeric oxazolines 7+7′ (Table 5, entries 20–23) nor the 2-aminothiazoline
derivative 8a (Table 5, entry 24) displayed any cytotoxicity against the same cell line.
Finally, we studied the cytotoxicity effect of iminooxazolidines 9a–c against A549 cell
lines. For instance, IC50 values between 6.2 ± 0.7 and 16.4 ± 1.5 µM were observed, with
iminooxazolidine 9c (Table 5, entry 27) as the most effective compound with an IC50 value
of 6.2 ± 0.7 µM. It appears rational to presume that the observed cytotoxic activity in
imonooxazolidines 9, which was not observed in oxazolines 7, could be due to the presence
of an amide group at the N–3 of the oxazoline ring.
Furthermore, MRC-5 non-malignant lung fibroblasts were tested to study the selec-
tive toxicity [49], and none of the synthesized phosphorus substituted N-functionalized
cyanoaziridines, 5-membered nitrogen-containing heterocycles, or doxorubicin exhibited
any toxicity toward the MRC-5 cell line (see Table 5).
3. Materials and Methods
3.1. Chemistry
3.1.1. General Experimental Information
Solvents for extraction and chromatography were of a technical grade. All solvents
used in reactions were freshly distilled and dried over molecular sieves 4 Å before use.
All other solvents and reagents were obtained from commercial sources (Sigma-Aldrich,
Spain) and recrystallized or distilled as necessary or were used without further purification.
All reactions were performed under an atmosphere of dry nitrogen. Melting points were
determined using the Büchi Melting Point B-540 apparatus and were uncorrected. IR
spectra were measured on a Nicolet iS10 Thermo Fisher Scientific spectrometer (Thermo
Scientific Inc., Waltham, MA, USA) as neat solids. Absorbance frequencies are given at
maximum of intensity in cm−1. High-resolution mass spectra (HRMS) were measured on
an Agilent 6530 Accurate-Mass QTOF LC/MS (Santa Clara, CA, USA) by a positive-ion
electrospray ionization (ESI) method with a time-of-flight Q-TOF system. Data are reported
in the form m/z (intensity relative to base = 100). 1H (300, 400 MHz), 13C (75, 100 MHz),
and 31P NMR (120, 160 MHz) spectra were recorded on Varian Unity Plus (Varian Inc.,
NMR Systems, Palo Alto, CA, USA) or on Bruker Avance 400 (Bruker BioSpin GmbH,
Rheinstetten, Germany) spectrometers, respectively, in CDCl3 at 25 ◦C. Chemical shifts (δH)
are reported in parts per million (ppm) with the internal chloroform signal at 7.24 ppm
as the standard for 1H NMR. Chemical shifts (δC and δP) are reported in parts per million
(ppm) with the internal chloroform signal at 77.0 ppm as the standard for 13C NMR, or
the external H3PO4 (50%) signal at 0.0 ppm as the standard for 31P NMR. All coupling
constants (J) values are given in Hz. 13C NMR spectra were recorded in a broadband
decoupled mode from hydrogen nuclei. Distortionless Enhanced Polarization Transfer
(DEPT) supported peak assignments for 13C NMR. The data are reported as s = singlet,
d = doublet, t = triplet, q = quartet, m = multiplet, dd = double doublet, bs = broad singlet.
Chromatographic purification was performed as flash chromatography using commercial
grades of silica gel finer than 230 mesh with pressure. Analytical thin layer chromatography
(TLC) was performed on precoated Merck silica gel 60 F254 TLC aluminium plates, and
spot visualized with UV light or permanganate stain. Cyanoaziridines 1 were prepared
according to procedures in the literature [16].
3.1.2. Experimental Procedure and Characterization Data for Compounds 2–9
General Procedure and Spectral Data for The Addition of 3,5-Dinitrobenzoyl Chloride to
Functionalized Cyanoaziridines
3,5-Dinitrobenzoyl chloride (1.4 g, 6 mmol, 1.2 eq) and Et3N (2.8 mL, 20 mmol, 4 eq)
were added to a 0 ◦C solution of cyanoaziridine (5 mmol, 1 eq) in CH2Cl2 (25 mL). The
reaction mixture was stirred at 0 ◦C until TLC showed the disappearance of the starting
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cyanoaziridine. The crude product was washed three times with a saturated NaCl solution
(15 mL) and water (15 mL) and extracted with CH2Cl2 (15 mL). The organic layers were
dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuum conditions,
and the resulting residue was purified by crystallization from Et2O/pentane or washed
with pentane.
(E)-(2S*,3S*)-1-(3,5-Dinitrobenzoyl)-3-(diphenylphosphoryl)-2-methylaziridine-2-carbonitrile
(2a), (1.97 g, 83%) was obtained as a grey solid from cyanoaziridine 1a (1.41 g, 5 mmol) after
24 h at 0 ◦C as described in the general procedure. The crude product was purified by
crystallization from Et2O/pentane (50:50) to give the title compound 2a; mp 120–122 ◦C; IR
(neat) vmax 3067, 2948, 2237, 1699, 1546, 1346, 1252, 1210, 1152 cm−1; 1H NMR (300 MHz,
CDCl3) δ 9.23 (t, 4JHH = 2.0 Hz, 1H, ArH), 9.08 (d, 4JHH = 2.0 Hz, 2H, ArH), 7.85–7.48 (m, 10H,
ArH), 3.86 (d, 2JPH = 20.5 Hz, 1H, CH-P), 2.17 (s, 3H, CH3) ppm; 13C {1H} NMR (75 MHz,
CDCl3) δ 171.8 (d, 3JPC = 3.0 Hz, C=O), 149.0 (Cquat), 135.1(Cquat), 133.5, 133.5, 133.4, 133.3,
131.3, 131.1, 131.1, 131.0, 129.7, 129.5, 129.4, 129.2, 129.0 (CAr),120.4 (Cquat), 116.6 (CN), 43.4
(d, 1JPC = 90.7 Hz, CH-P), 37.0 (d, 2JPC = 2.5 Hz, Cquat), 16.9 (CH3) ppm; 31P NMR (120 MHz,
CDCl3) δ 21.9 ppm; ESI-HRMS (CI) m/z calculated for C23H18N4O6P ([M + H]+) 477.0964
found 477.0971 (See Supplementary Materials).
(E)-(2S*,3S*)-1-(3,5-Dinitrobenzoyl)-3-(diphenylphosphoryl)-2-ethylaziridine-2-carbonitrile
(2b), (1.95 g, 80%) was obtained as a grey solid from cyanoaziridine 1b (1.48 g, 5 mmol)
after 24 h at 0 ◦C as described in the general procedure. The crude product was purified by
crystallization from Et2O/pentane (50:50) to give the title compound 2b; mp 201–203 ◦C; IR
(neat) vmax 3101, 2884, 2237, 1710, 1630, 1544, 1460, 1441, 1344, 1294, 1202 1147, 1122 cm−1;
1H NMR (300 MHz, CDCl3) δ 9.24 (t, 4JHH = 2.1 Hz, 1H, ArH), 9.11 (d, 4JHH = 2.1 Hz,
2H, ArH), 7.90–7.47 (m, 10H, ArH), 3.90 (d, 2JPH = 20.4 Hz, 1H, CH-P), 2.61–2.46 (m, 2H,
CH2), 1.08 (t, 3JHH = 7.4 Hz, 3H, CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 172.4
(d, 3JPC = 3.3 Hz, C=O), 148.9 (Cquat), 135.1 (Cquat), 133.5, 133.4, 133.3, 133.2, 131.2, 131.2,
131.1, 131.0, 129.6, 129.5, 129.3, 129.2, 129.1, 123.4 (CAr), 115.6 (CN), 43.6 (d, 1JPC = 90.6 Hz,
CH-P), 43.2 (d, 2JPC = 2.6 Hz, Cquat), 24.2 (CH2), 10.5 (CH3) ppm; 31P NMR (120 MHz,
CDCl3) δ 21.4 ppm; ESI-HRMS (CI) m/z calculated for C24H20N4O6P ([M + H]+) 491.1120
found 491.1135.
Diethyl (E)-[(2S*,3S*)-3-cyano-1-(3,5-dinitrobenzoyl)-3-methylaziridin-2-yl]phosphonate
(2c), (1.92 g, 93%) was obtained as a brown oil from cyanoaziridine 1c (1.09 g, 5 mmol)
after 24 h at 0 ◦C as described in the general procedure. The crude product was washed
with pentane to give the title compound 2c; Rf: 0.5 (AcOEt); IR (neat) vmax 3112, 2984, 2246,
1710, 1627, 1552, 1344, 1294, 1255, 1041, 1022 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.25 (t,
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4JHH = 2.1 Hz, 1H, ArH), 9.05 (d, 4JHH = 2.1 Hz, 2H, ArH), 4.30–4.17 (m, 4H, OCH2CH3),
3.37 (d, 2JPH = 11.9 Hz, 1H, CH-P), 2.09 (s, 3H, CH3), 1.42–1.34 (m, 6H, OCH2CH3) ppm; 13C
{1H} NMR (75 MHz, CDCl3) δ 171.4 (d, 3JPC = 5.0 Hz, C=O), 149.1 (Cquat), 134.8 (Cquat), 128.9,
123.4 (CAr), 116.3 (3JPC = 2.1 Hz, CN), 64.2 (d, 2JPC = 6.1 Hz, OCH2), 63.7 (d, 2JPC = 6.5 Hz,
OCH2) 40.4 (d, 1JPC = 202.3 Hz, CH-P), 35.8 (d, 2JPC = 2.7 Hz, Cquat), 17.6 (CH3), 16.5 (d,
3JPC = 5.9 Hz, OCH2CH3), 16.4 (d, 3JPC = 5.9 Hz, OCH2CH3) ppm; 31P NMR (120 MHz,
CDCl3) δ 12.3 ppm; ESI-HRMS (CI) m/z calculated for C15H18N4O8P ([M + H]+) 413.0862
found 413.0857.
General Procedure and Spectral Data for Compound 3a
To a stirred solution of N-functionalized cyanoaziridine 2a (5 mmol, 1 eq) in THF
(15 mL), NaI (0.02 g, 1 mmol, 0.2 eq) was added dropwise. The mixture was heated at 60 ◦C
for 24 h until TLC showed the disappearance of the starting cyanoaziridine. The reaction
mixture was concentrated to dryness in vacuum conditions to remove THF. The crude
product was washed three times with water (15 mL) and extracted with CH2Cl2 (15 mL).
The organic layer was dried over anhydrous MgSO4, filtered, and concentrated to dryness
in vacuum conditions. The crude product was purified by flash-column chromatography.
(E)-(4S*,5S*)-2-(3,5-Dinitrophenyl)-5-(diphenylphosphoryl)-4-methyl-4,5-dihydrooxazole-
4-carbonitrile (3a), (1.56 g, 65%) was obtained as a yellow solid from cyanoaziridine 2a
(2.38 g, 5 mmol) after 24 h of heating in THF as described in the general procedure. The
crude product was purified by flash-column chromatography (SiO2, AcOEt/hexane 25:75)
to give the title compound 3a; mp 129–131 ◦C; IR (neat) vmax 3103, 2934, 2243, 1655, 1546,
1438, 1352, 1197, 1119 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.19 (t, 4JHH = 2.1 Hz, 1H,
ArH), 8.99 (d, 4JHH = 2.1 Hz, 2H, ArH), 7.98–7.52 (m, 10H, ArH), 5.60 (d, 2JPH = 6.7 Hz, 1H,
CH-P), 1.80 (s, 3H, CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 161.7 (d, 3JPC = 5.6 Hz,
Cquat), 148.8, 133.8, 133.8, 133.4, 133.3, 131.4, 131.3, 131.2, 131.1, 129.9, 129.7, 129.4, 129.3,
128.8, 122.2 (CAr),119.8 (d, 3JPC = 8.9 Hz, CN), 108.1 (Cquat), 83.2 (d, 1JPC = 76.7 Hz, CH-
P), 68.3 (d, 2JPC = 2.0 Hz, Cquat), 23.0 (d, 3JPC = 5.2 Hz, CH3) ppm; 31P NMR (120 MHz,
CDCl3) δ 22.5 ppm; ESI-HRMS (CI) m/z calculated for C23H18N4O6P ([M + H]+) 477.0964
found 477.0965.
General Procedures and Spectral Data for The Addition of Isocyanates to Functionalized
Cyanoaziridines 1
Method A. To a 0 ◦C solution of cyanoaziridine (5 mmol, 1 eq) in CH2Cl2 (25 mL)
the corresponding isocyanate (6 mmol, 1.2 eq) was added dropwise. The reaction mixture
was allowed to reach room temperature and stirred for 6–24 h. The crude products
were concentrated to dryness in vacuum conditions and were purified by crystallization.
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Method B. To a 0 ◦C solution of cyanoaziridine (5 mmol, 1 eq) in CH2Cl2 (25 mL) phenyl
isocyanate (15 mmol, 3 eq) and Sc (OTf)3 (0.49 g, 1 mmol, 0.2 eq) were added dropwise.
The reaction mixture was stirred at 0 ◦C for 5 h until TLC showed the disappearance of
the starting cyanoaziridine. The reaction mixture was washed with water (3 × 15 mL)
and extracted with CH2Cl2 (15 mL). The organic layer was dried over anhydrous MgSO4,
filtered, and concentrated to dryness in vacuum conditions. The crude product was
purified by crystallization from Et2O. Method C. To a solution of cyanoaziridine (5 mmol,
1 eq) in CH2Cl2 (25 mL) the corresponding aliphatic isocyanate (10 mmol, 2 eq) and
ZnCl2 (0.85 g, 6.25 mmol, 1.25 eq) were added dropwise. The reaction mixture was
stirred at room temperature for 5–48 h until TLC showed the disappearance of the starting
cyanoaziridine. The reaction mixture was washed with saturated NH4Cl (1 × 15 mL) and
water (3 × 15 mL) and extracted with CH2Cl2 (15 mL). The organic layers were dried over
anhydrous MgSO4, filtered, and concentrated to dryness in vacuum conditions. The crude
product was purified by crystallization.
(E)-(2S*,3S*)-2-Cyano-3-(diphenylphosphoryl)-2-methyl-N-phenylaziridine-1-carboxamide
(5a), (1.27 g, 63%) was obtained as a white solid from cyanoaziridine 1a (1.41 g, 5 mmol) and
phenylisocyanate (0.65 mL, 6 mmol, 1.2 eq) as described in the general procedure (method
A). The crude product was purified by crystallization from Et2O to give the title compound
5a. (1.42 g, 71%) obtained as an orange pale solid from cyanoaziridine 1a (1.41 g, 5 mmol),
phenylisocyanate (0.65 mL, 6 mmol, 1.2 eq) and Sc(OTf)3 (1 mmol, 0.49 g) as described
in the general procedure (method B). The crude product was purified by crystallization
from Et2O to give the title compound 5a; mp 179–181 ◦C; IR (neat) vmax 3220, 3053, 2926,
2256, 1710, 1596, 1544, 1435, 1252, 1202, 1127 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.11 (bs,
1H, NH), 7.88–7.07 (m, 15H, ArH), 3.76 (d, 2JPH = 23.1 Hz, 1H, CH-P), 1.92 (s, 3H, CH3)
ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 157.2 (C=O), 137.8 (Cquat), 133.1, 133.1, 133.1, 133.0,
131.6, 131.4, 131.2, 131.2, 131.0, 130.1, 130.0, 129.5, 129.4, 129.3, 129.2, 129.1, 124.6, 120.1
(CAr), 117.1 (CN), 41.3 (d, 1JPC = 102.1 Hz, CH-P), 37.4 (Cquat), 17.9 (CH3) ppm; 31P NMR
(120 MHz, CDCl3) δ 23.4 ppm; ESI-HRMS (CI) m/z calculated for C23H21N3O2P ([M + H]+)
402.1371 found 402.1374.
Diethyl (E)-[(2S*,3S*)-3-cyano-3-methyl-1-(phenylcarbamoyl)aziridin-2-yl]phosphonate
(5b), (1.65 g, 98%) was obtained as a white solid from cyanoaziridine 1c (1.09 g, 5 mmol)
and phenylisocyanate (0.65 mL, 6 mmol, 1.2 eq) as described in the general procedure
(method A). The crude product was purified by crystallization from CH2Cl2/pentane to
give the title compound 5b; mp 137–139 ◦C; IR (neat) vmax 3253, 3065, 2984, 2240, 1716, 1607,
1544, 1499, 1444, 1249, 1044, 1024 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.30 (bs, 1H, NH),
7.48–7.09 (m, 5H, ArH), 4.25–4.15 (m, 4H, OCH2CH3), 3.29 (d, 2JPH = 13.6 Hz, 1H, CH-P),
1.92 (s, 3H, CH3), 1.40–1.32 (m, 6H, OCH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3)
δ 156.6 (C=O), 137.3 (Cquat), 129.2, 124.8, 120.0 (CAr), 116.9 (CN), 63.9 (d, 2JPC = 5.4 Hz,
OCH2), 63.3 (d, 2JPC = 6.0 Hz, OCH2) 38.7 (d, 1JPC = 207.4 Hz, CH-P), 36.0 (Cquat), 18.2
(CH3), 16.6 (d, 3JPC = 4.9 Hz, OCH2CH3), 16.5 (d, 3JPC = 4.7 Hz, OCH2CH3) ppm; 31P NMR
(120 MHz, CDCl3) δ 14.6 ppm; ESI-HRMS (CI) m/z calculated for C15H21N3O4P ([M + H]+)
338.1270 found 338.1264.
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(E)-(2S*,3S*)-2-Cyano-3-(diphenylphosphoryl)-2-methyl-N-(p-tolyl) aziridine-1-carboxamide
(5c), (1.70 g, 82%) was obtained as a yellow solid from cyanoaziridine 1a (1.41 g, 5 mmol) and
p-tolyl isocyanate (0.76 mL, 6 mmol, 1.2 eq) as described in the general procedure (method A).
The crude product was purified by crystallization from Et2O to give the title compound 5c;
mp 193–195 ◦C; IR (neat) vmax 3237, 3056, 2917, 2254, 1710, 1599, 1546, 1539, 1408, 1249,
1197 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.17 (bs, 1H, NH), 7.86–7.06 (m, 14H, ArH), 3.76 (d,
2JPH = 23.0 Hz, 1H, CH-P), 2.28 (s, 3H, CH3), 1.92 (s, 3H, CH3) ppm; 13C {1H} NMR (75 MHz,
CDCl3) δ 157.1 (d, 3JPC = 4.2 Hz, C=O), 135.2 (Cquat), 134.2 (Cquat), 133.0, 133.0, 131.3, 131.2,
131.1, 131.0, 129.5, 129.4, 129.3, 129.1, 120.2, 120.0, (CAr), 117.1 (CN), 41.2 (d, 1JPC = 100.5 Hz,
CH-P), 37.3 (d, 2JPC = 3.1 Hz, Cquat), 21.0 (CH3), 17.9 (CH3) ppm; 31P NMR (120 MHz,
CDCl3) δ 23.6 ppm; ESI-HRMS (CI) m/z calculated for C24H23N3O2P ([M + H]+) 416.1528
found 416.1532.
Diethyl (E)-[(2S*,3S*)-3-cyano-3-methyl-1-(p-tolylcarbamoyl)aziridin-2-yl]phosphonate (5d),
(1.40 g, 80%) was obtained as a pale yellow solid from cyanoaziridine 1c (1.09 g, 5 mmol)
and p-tolyl isocyanate (0.76 mL, 6 mmol, 1.2 eq) as described in the general procedure
(method A). The crude product was purified by crystallization from CH2Cl2/pentane to
give the title compound 5d; mp 140–142 ◦C; IR (neat) vmax 3256, 3040, 2987, 2240, 1710,
1607, 1538, 1444, 1516, 1321, 1247, 1039 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.15 (bs, 1H,
NH), 7.33 (d, 3JHH = 7.9 Hz, 2H, ArH), 7.09 (d, 3JHH = 7.9 Hz, 2H, ArH), 4.24–4.14 (m, 4H,
OCH2CH3), 3.28 (d, 2JPH = 13.5 Hz, 1H, CH-P), 2.28 (s, 3H, CH3), 1.91 (s, 3H, CH3), 1.39–1.32
(m, 6H, OCH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 156.6 (d, 3JPC = 5.9 Hz, C=O),
134.9 (Cquat), 134.3 (Cquat), 129.5, 120.1 (CAr), 116.9 (CN), 63.9 (d, 2JPC = 6.2 Hz, OCH2),
63.2 (d, 2JPC = 6.5 Hz, OCH2), 38.4 (d, 1JPC = 206.8 Hz, CH-P), 36.0 (d, 2JPC = 2.2 Hz,
Cquat), 20.9 (CH3), 18.1 (CH3), 16.5 (d, 3JPC = 6.0 Hz, OCH2CH3), 16.4 (d, 3JPC = 6.0 Hz,
OCH2CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 14.8 ppm; ESI-HRMS (CI) m/z calculated
for C16H23N3O4P ([M + H]+) 352.1426 found 352.1419.
(E)-(2S*,3S*)-2-Cyano-3-(diphenylphosphoryl)-2-ethyl-N-tosylaziridine-1-carboxamide (5e),
(2.12 g, 86%) was obtained as a white solid from cyanoaziridine 1b (1.48 g, 5 mmol) and
p-toluenesulfonyl isocyanate (0.92 mL, 6 mmol, 1.2 eq) as described in the general pro-
cedure (method A). The crude product was purified by crystallization from Et2O to give
the title compound 5e; mp 201–203 ◦C; IR (neat) vmax 3257, 2931, 2245, 1743, 1605, 1444,
1360, 1242, 1124, 1094 cm−1; 1H NMR (400 MHz, MeOD) δ 7.92–7.38 (m, 14H, ArH), 3.39
(d, 2JPH = 23.4 Hz, 1H, CH-P), 1.97 (m, 2H, CH2), 2.44 (s, 3H, CH3), 1.02 (t, 3JHH = 7.4 Hz,
3H, CH3) ppm; 13C {1H} NMR (75 MHz, MeOD) δ 153.5 (C=O), 146.0 (Cquat), 137.8 (Cquat),
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134.2, 134.2, 133.9, 133.9, 132.2, 132.1, 132.1, 132.0, 130.5, 130.4, 130.3, 130.2, 130.0, 129.0
(CAr), 120.4 (CN), 39.5 (d, 1JPC = 101.6 Hz, CH-P), 36.6 (Cquat), 25.2 (CH2), 21.5 (CH3), 11.1
(CH3) ppm; 31P NMR (120 MHz, MeOD) δ 27.2 ppm; ESI-HRMS (CI) m/z calculated for
C25H25N3O4PS ([M + H]+) 494.1303 found 494.1292.
Diethyl (E)-[(2S*,3S*)-3-cyano-3-methyl-1-(tosylcarbamoyl)aziridin-2-yl]phosphonate (5f),
(1.64 g, 79%) was obtained as a waxy white solid from cyanoaziridine 1c (1.09 g, 5 mmol)
and p-toluenesulfonyl isocyanate (0.92 mL, 6 mmol, 1.2 eq) as described in the general proce-
dure (method A). The crude product was purified by crystallization from CH2Cl2/pentane
to give the title compound 5f; Rf: 0.4 (AcOEt). IR (neat) vmax 3248, 3092, 2992, 2237, 1738,
1649, 1596, 1446, 1335, 1247, 1160, 1047, 1027 cm−1; 1H NMR (300 MHz, CDCl3) δ 10.50
(bs, 1H, NH), 7.89–7.78 (m, 4H, ArH), 4.24–4.10 (m, 4H, OCH2CH3), 3.04 (d, 2JPH = 13.2 Hz,
1H, CH-P), 2.38 (s, 3H, CH3), 1.83 (s, 3H, CH3), 1.37–1.28 (m, 6H, OCH2CH3) ppm; 13C
{1H} NMR (75 MHz, CDCl3) δ 155.3 (d, 3JPC = 6.6 Hz, C=O), 145.3 (Cquat), 135.1 (Cquat),
129.8, 129.7, 128.6, 128.1, 126.5 (CAr), 116.2 (CN), 64.3 (d, 2JPC = 6.0 Hz, OCH2), 63.8
(d, 2JPC = 6.4 Hz, OCH2), 38.9 (d, 1JPC = 206.6 Hz, CH-P), 36.3 (d, 2JPC = 3.0 Hz, Cquat), 21.8
(CH3), 17.7 (CH3), 16.5 (d, 3JPC = 6.3 Hz, OCH2CH3), 16.4 (d, 3JPC = 6.2 Hz, OCH2CH3) ppm;
31P NMR (120 MHz) δ 13.3 ppm; ESI-HRMS (CI) m/z calculated for C16H23N3O6PS
([M + H]+) 416.1045 found 416.1038.
(E)-(2S*,3S*)-2-Cyano-3-(diphenylphosphoryl)-N-ethyl-2-methylaziridine-1-carboxamide (5g),
(1.51 g, 86%) was obtained as a pale pink solid from cyanoaziridine 1a (1.41 g, 5 mmol) and
ethyl isocyanate (0.79 mL, 10 mmol, 2 eq) as described in the general procedure (method
C). The crude product was purified by crystallization from Et2O/pentane 50:50 to give the
title compound 5g; mp 182–184 ◦C; IR (neat) vmax 3253, 3053, 2976, 2240, 1702, 1544, 1438,
1283, 1258, 1191, 1124 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.84–7.46 (m, 10H, ArH), 5.98 (t,
3JHH = 5.9 Hz, 1H, NH), 3.65 (d, 2JPH = 22.1 Hz, 1H, CH-P), 3.37–3.18 (m, 2H, NHCH2CH3),
1.85 (s, 3H, CH3), 1.13 (t, 3JHH = 7.3 Hz, NHCH2CH3) ppm; 13C {1H} NMR (100 MHz, CDCl3)
δ 159.1 (d, 3JPC = 4.6 Hz, C=O), 133.0, 132.9, 132.8, 132.8, 131.6, 131.4, 131.3, 131.1, 131.1,
130.6, 130.3, 129.3, 129.2, 129.1, 129.0 (CAr), 117.1 (CN), 41.6 (d, 1JPC = 100.1 Hz, CH-P), 36.7
(d, 2JPC = 3.4 Hz, Cquat), 36.4 (NHCH2CH3), 18.1 (CH3), 15.1 (NHCH2CH3) ppm; 31P NMR
(120 MHz, CDCl3) δ 23.1 ppm; ESI-HRMS (CI) m/z calculated for C19H21N3O2P ([M + H]+)
354.1371 found 354.1372.
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Diethyl (E)-[(2S*,3S*)-3-cyano-1-(ethylcarbamoyl)-3-methylaziridin-2-yl]phosphonate (5h),
(0.85 g, 59%) was obtained as a waxy solid from cyanoaziridine 1c (1.09 g, 5 mmol)
and ethyl isocyanate (0.79 mL, 10 mmol, 2 eq) as described in the general procedure
(method C). The crude product was purified by crystallization from Et2O/pentane 50:50
to give the title compound 5h; Rf: 0.3 (AcOEt); IR (neat) vmax 3281, 3062, 2987, 2243,
1699, 1541, 1455, 1385, 1371, 1252, 1160, 1044, 1039 cm−1; 1H NMR (300 MHz, CDCl3)
δ 6.03 (bs, 1H, NH), 4.19–4.09 (m, 4H, OCH2CH3), 3.36–3.18 (m, 2H, NHCH2CH3), 3.12
(d, 2JPH = 13.8 Hz, 1H, CH-P), 1.79 (s, 3H, CH3), 1.34–1.28 (m, 6H, OCH2CH3) 1.13 (t,
3JHH = 7.2 Hz, NHCH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 158.8 (d, 3JPC = 6.4
Hz, C=O), 116.9 (CN), 63.7 (d, 2JPC = 5.7 Hz, OCH2), 63.0 (d, 2JPC = 6.2 Hz, OCH2), 38.6 (d,
1JPC = 207.0 Hz, CH-P), 36.2 (NHCH2CH3), 35.3 (d, 2JPC = 3.2 Hz, Cquat), 18.2 (CH3), 16.4
(d, 3JPC = 5.2 Hz, OCH2CH3), 16.4 (d, 3JPC = 5.3 Hz, OCH2CH3), 15.0 (NHCH2CH3) ppm;
31P NMR (120 MHz, CDCl3) δ 15.1 ppm; ESI-HRMS (CI) m/z calculated for C11H21N3O4P
([M + H]+) 290.1270 found 290.1275.
(E)-(2S*,3S*)-N-(tert-Butyl)-2-cyano-3-(diphenylphosphoryl)-2-methylaziridine-1-carboxamide
(5i), (1.39 g, 73%) was obtained as a white solid from cyanoaziridine 1a (1.41 g, 5 mmol) and
tert-butyl isocyanate (1.14 mL, 10 mmol, 2 eq) as described in the general procedure (method
C). The crude product was purified by crystallization from Et2O/pentane 50:50 to give the
title compound 5i; mp 166–168 ◦C; IR (neat) vmax 3259, 3056, 2976, 2237, 1707, 1541, 1452, 1441,
1369, 1285, 1208, 1127 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.82–7.48 (m, 10H, ArH), 5.53 (s,
1H, NH), 3.62 (d, 2JPH = 22.1 Hz, 1H, CH-P), 1.85 (s, 3H, CH3), 1.33 (s, 9H, C(CH3)3) ppm;
13C {1H} NMR (75 MHz, CDCl3) δ 157.4 (d, 3JPC = 4.6 Hz, C=O), 132.9, 132.9, 132.8, 132.8,
131.9, 131.6, 131.4, 131.3, 131.1, 131.0, 130.5, 130.2, 129.3, 129.2, 129.1, 129.0 (CAr), 117.0 (CN),
52.1 (C(CH)3)3), 41.2 (d, 1JPC = 99.9 Hz, CH-P), 36.5 (d, 2JPC = 3.5 Hz, Cquat), 28.7 (C(CH)3),
18.1 (CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 23.1 ppm; ESI-HRMS (CI) m/z calculated for
C21H25N3O2P ([M + H]+) 382.1684 found 382.1687.
Diethyl (E)-[(2S*,3S*)-1-(tert-butylcarbamoyl)-3-cyano-3-methylaziridin-2-yl]phosphonate
(5j), (1.19 g, 75%) was obtained as a white solid from cyanoaziridine 1c (1.09 g, 5 mmol)
and tert-butyl isocyanate (1.14 mL, 10 mmol, 2 eq) as described in the general procedure
(method C). The crude product was purified by flash-column chromatography (SiO2,
AcOEt/hexane 20:80) to give the title compound 5j; mp 96–98 ◦C; IR (neat) vmax 3284, 3051,
2979, 2246, 1705, 1538, 1477, 1457, 1394, 1369, 1260, 1160, 1038 cm−1; 1H NMR (300 MHz,
CDCl3) δ 5.45 (bs, 1H, NH), 4.21–4.11 (m, 4H, OCH2CH3), 3.13 (d, 2JPH = 13.6 Hz, 1H, CH-P),
1.81 (s, 3H, CH3), 1.36–1.30 (m, 15H, C(CH3)3 + OCH2CH3) ppm; 13C {1H} NMR (75 MHz,
CDCl3) δ 157.1 (d, 3JPC = 6.7 Hz, C=O), 116.9 (d, 3JPC = 2.4 Hz, CN), 63.7 (d, 2JPC = 6.1 Hz,
OCH2), 63.0 (d, 2JPC = 6.5 Hz, OCH2), 52.1 (C(CH)3)3), 38.3 (d, 1JPC = 207.1 Hz, CH-P), 35.3
(d, 2JPC = 3.4 Hz, Cquat), 28.7 (C(CH)3), 18.4 (CH3), 16.5 (d, 3JPC = 5.9 Hz, OCH2CH3), 16.4
(d, 3JPC = 5.6 Hz, OCH2CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 15.5 ppm; ESI-HRMS
(CI) m/z calculated for C13H24N3NaO4P ([M + Na]+) 340.1402 found 340.1400.
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(E)-(2S*,3S*)-N-(tert-Butyl)-2-cyano-3-(diphenylphosphoryl)-2-ethylaziridine-1-carboxamide
(5k), (1.27 g, 64%) was obtained as a white solid from cyanoaziridine 1b (1.48 g, 5 mmol) and
tert-butyl isocyanate (1.14 mL, 10 mmol, 2 eq) as described in the general procedure (method C).
The crude product was purified by flash-column chromatography (SiO2, AcOEt/hexane 50:50)
to give the title compound 5k; mp 197–199 ◦C; IR (neat) vmax 3262, 2976, 2240, 1718, 1499, 1457,
1438, 1369, 1274, 1199, 1122 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.83–7.45 (m, 10H, ArH), 5.43
(s, 1H, NH), 3.67 (d, 2JPH = 22.2 Hz, 1H, CH-P), 2.34–2.24 (m, 1H, CH2CH3), 2.01–1.99 (m, 1H,
CH2CH3), 1.33 (s, 9H, C(CH3)3, 1.09 (t, 3JHH = 1.9 Hz, 3H, CH2CH3) ppm; 13C {1H} NMR
(100 MHz, CDCl3) δ 157.5 (C=O), 132.9, 132.8, 131.3, 131.2, 131.1, 131.0, 129.3, 129.2, 129.1, 129.0
(CAr), 116.1 (CN), 52.0 (C(CH3)3), 42.3 (d, 2JPC = 1.7 Hz, Cquat), 41.9 (d, 1JPC = 117.2 Hz, CH-P),
28.7 (C(CH)3), 24.6 (CH2CH3), 10.8 (CH2CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 22.8 ppm;
ESI-HRMS (CI) m/z calculated for C22H27N3O2P ([M + H]+) 396.1841 found 396.1847.
General Procedures and Spectral Data for The Addition of Ethoxycarbonyl Isothiocyanate
to Functionalized Cyanoaziridines 1
Method A. To a −30 ◦C solution of cyanoaziridine 1 (5 mmol, 1 eq) in CH2Cl2 (25 mL)
ethoxycarbonyl isothiocyanate (6 mmol, 1.2 eq) was added dropwise. The reaction mixture
was stirred at −30 ◦C for 6–8 h until TLC showed the disappearance of the starting
cyanoaziridine. The crude products were concentrated to dryness in vacuum conditions
and were purified by crystallization. Method B. To a 0 ◦C solution of cyanoaziridine 1
(5 mmol, 1 eq) in CH2Cl2 (25 mL) ethoxycarbonyl isothiocyanate (6 mmol, 1.2 eq) was
added dropwise. The reaction mixture was allowed to reach room temperature and stirred
for 6–24 h. The crude product was concentrated to dryness in vacuum conditions and was
purified by crystallization.
Ethyl (E)-[(2S*,3S*)-2-cyano-3-(diphenylphosphoryl)-2-methylaziridine-1-carbonothioyl]carbamate
(6a), (1.47 g, 71%) was obtained as an orange solid from cyanoaziridine 1a (1.41 g, 5 mmol) and
ethoxycarbonyl isothiocyanate (0.71 mL, 6 mmol, 1.2 eq) as described in the general procedure
(method A). The crude product was purified by crystallization from Et2O to give the title com-
pound 6a. (1.66 g, 80%) which was obtained as an orange solid from cyanoaziridine 1a (1.41 g,
5 mmol) and ethoxycarbonyl isothiocyanate (0.71 mL, 6 mmol, 1.2 eq) as described in the general
procedure (method B). The crude product was purified by crystallization from Et2O to give the
title compound 6a; mp 156–158 ◦C; IR (neat) vmax 3406, 3147, 2984, 2254, 1771, 1593, 1491, 1438,
1383, 1233, 1152, 1122, 1041 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.43 (bs, 1H, NH), 7.94–7.42 (m,
10H, ArH), 4.17 (q, 3JHH = 7.1 Hz, 2H, OCH2), 3.92 (d, 2JPH = 20.0 Hz, 1H, CH-P), 1.97 (s, 3H,
CH3). A value of 1.23 (t, 3JHH = 7.1 Hz, 3H, CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 190.5
(d, 3JPC = 4.6 Hz, C=S), 149.0 (C=O), 133.0, 133.0, 132.8, 132.8, 131.8, 131.7, 131.5, 131.2, 131.1, 130.9,
130.1, 129.4, 129.3, 129.1, 128.8, 128.6 (CAr), 116.5 (CN), 63.0 (CH2), 48.8 (d, 1JPC = 94.5 Hz, CH-P),
42.4 (d, 2JPC = 3.2 Hz, Cquat), 18.6 (CH3), 14.2 (CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 22.7 ppm;
ESI-HRMS (CI) m/z calculated for C20H21N3O3PS ([M + H]+) 414.1041, found 414.1041.
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Ethyl (E)-[(2S*,3S*)-2-cyano-3-(diphenylphosphoryl)-2-ethylaziridine-1-carbonothioyl]carbamate
(6b), (1.82 g, 85%) was obtained as a pale yellow solid from cyanoaziridine 1b (1.48 g, 5 mmol) and
ethoxycarbonyl isothiocyanate (0.71 mL, 6 mmol, 1.2 eq) as described in the general procedure
(method A). The crude product was purified by crystallization from Et2O to give the title
compound 6b; mp 179–181 ◦C; IR (neat) vmax 3409, 3062, 2981, 2254, 2237, 1752, 1541, 1438,
1230, 1197, 1163, 1044 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.96 (bs, 1H, NH), 7.97–7.44 (m, 10H,
ArH), 4.20 (q, 3JHH = 7.2 Hz, 2H, OCH2), 3.96 (d, 2JPH = 20.2 Hz, 1H, CH-P), 2.59–2.50 (m, 1H,
CH2), 2.37–2.28 (m, 1H, CH2). A value of 1.27 (t, 3JHH = 7.2 Hz, 3H, CH3), 0.99 (t, 3JHH = 7.5 Hz,
CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 190.1 (d, 3JPC = 4.4 Hz, C=S), 149.0 (C=O), 133.1,
133.0, 132.8, 132.8, 131.8, 131.6, 131.5, 131.4, 131.3, 131.2, 130.1, 129.9, 129.3, 129.2, 128.9, 128.7
(CAr), 115.4 (CN), 63.2 (OCH2), 48.8 (d, 1JPC = 94.4 Hz, CH-P), 48.0 (d, 2JPC = 3.1 Hz, Cquat), 24.6
(CH2), 14.3 (CH3), 10.4 (CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 21.8 ppm; ESI-HRMS (CI)
m/z calculated for C21H23N3O3PS ([M + H]+) 428.1198, found 428.1204.
Ethyl (E)-[(2S*,3S*)-2-cyano-3-(diethoxyphosphoryl)-2-methylaziridine-1-carbonothioyl]carbamate
(6c), (1.50 g, 86%) was obtained as an orange solid from cyanoaziridine 1c (1.09 g, 5 mmol) and
ethoxycarbonyl isothiocyanate (0.71 mL, 6 mmol, 1.2 eq) as described in the general procedure
(method B). The crude product was purified by crystallization from Et2O/pentane to give the
title compound 6c; mp 116–118 ◦C; IR (neat) vmax 3395, 3162, 2987, 2251, 1774, 1491, 1385,
1241, 1158, 1041 cm−1; 1H NMR (300 MHz, CDCl3) δ 9.03 (bs, 1H, NH), 4.30–4.14 (m, 6H,
OCH2CH3 + CH2CH3), 3.41 (d, 2JPH = 12.3 Hz, 1H, CH-P), 1.98 (s, 3H, CH3), 1.38–1.27 (m, 9H,
OCH2CH3 + CH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 190.3 (d, 3JPC = 6.7 Hz, C=S),
148.7 (C=O), 116.4 (d, 3JPC = 2.3 Hz, CN), 64.2 (d, 2JPC = 5.8 Hz, OCH2CH3), 63.3 (d, 2JPC = 6.9 Hz,
OCH2CH3), 63.2 (CH2), 45.8 (d, 1JPC = 201.7 Hz, CH-P), 41.8 (d, 2JPC = 3.2 Hz, Cquat), 18.6 (CH3),
16.5 (d, 3JPC = 4.0 Hz, OCH2CH3), 16.4 (d, 3JPC = 6.0 Hz, OCH2CH3), 14.2 (CH2CH3) ppm;
31P NMR (120 MHz, CDCl3) δ 13.3 ppm; ESI-HRMS (CI) m/z calculated for C12H21N3O5PS
([M + H]+) 350.0940 found 350.0932.
General Procedure and Spectral Data for The Reaction of NaI with N-Carbamoyl
Cyanoaziridines 7
To a stirred solution of N-functionalized cyanoaziridine 5 (5 mmol, 1 eq) in THF (15 mL),
NaI (0.02 g, 1 mmol, 0.2 eq) was added dropwise. The mixture was heated at 60 ◦C for
24 h until TLC showed the disappearance of the starting cyanoaziridine. NaI was filtered
through a sintered glass vacuum filtration funnel with celite and washed with THF. The
filtrate was concentrated to dryness in vacuum conditions and the resulting residue was
purified by flash-column chromatography.
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(4S*,5S*)-5-(Diphenylphosphoryl)-4-methyl-2-(phenylamino)-4,5-dihydrooxazole-4-carbonitrile
(7a) and (4S*,5S*)-4-(diphenylphosphoryl)-5-methyl-2-(phenylamino)-4,5-dihydrooxazole-5-
carbonitrile (7′a), (0.90 g, 45%) were obtained as yellow solids from N-functionalized cyanoaziri-
dine 5a (2.00 g, 5 mmol) as described in the general procedure. The crude product was
purified by flash-column chromatography (SiO2, AcOEt/hexane 50:50) to give the minor
regioisomer; mp 117–119 ◦C; IR (neat) vmax 3420, 3057, 2981, 2237, 1674, 1438, 1402, 1199,
1122 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.95–7.20 (m, 15H, ArH), 4.23 (bs, 1H, NH), 3.00 (d,
2JPH = 16.2 Hz, 1H, CH-P), 1.76 (s, 3H, CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 164.6
(d, 3JPC = 5.9 Hz, C=N), 132.9, 132.1, 131.9, 131.2, 131.1, 130.4, 130.0, 129.4, 129.2, 129.1, 128.9,
126.8 (CAr), 127.6 (CN), 51.8 (d, 1JPC = 95.5 Hz, CH-P), 29.8 (Cquat), 12.2 (CH3) ppm; 31P NMR
(120 MHz, CDCl3) δ 21.0 ppm; ESI-HRMS (CI) m/z calculated for C23H21N3O2P ([M + H]+)
402.1371 found 402.1368.
Diethyl (E)-[(4S*,5S*)-4-cyano-4-methyl-2-(phenylamino)-4,5-dihydroozazol-5-yl]phosphonate
(7b) and diethyl (E)-[(4S*,5S*)-5-cyano-5-methyl-2-(phenylamino)-4,5-dihydroozazol-4-
yl]phosphonate (7′b), (1.16 g, 69%) were obtained as waxy white solids from N-functionalized
cyanoaziridine 5b (1.68 g, 5 mmol) as described in the general procedure. The crude product
was purified by flash-column chromatography (SiO2, AcOEt) to give the title compound 7
as a mixture of two regioisomers 7b + 7′b; Rf: 0.1 (AcOEt); IR (neat) vmax 3370, 3061, 2990,
2240, 1666, 1499, 1402, 1255, 1158, 1052, 1019 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.10 (bs,
1H, NH), 7.52–7.12 (m, 11H, ArH + NH), 4.32–4.20 (m, 8H, OCH2), 2.65 (d, 2JPH = 11.0 Hz,
1H, CH-P)major, 2.62 (d, 2JPH = 11.1 Hz, 1H, CH-P)minor, 1.89 (s, 3H, CH3)major, 1.84 (s, 3H,
CH3)minor, 1.40–1.33 (m, 12H, OCH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 166.5 (d,
3JPC = 3.7 Hz, C=N)minor, 161.8 (d, 3JPC = 4.5 Hz, C=N)major, 132.4 (Cquat), 130.9 (Cquat),
130.3, 129.7, 129.3, 128.7, 127.7, 127.0, 126.7 (CAr), 121.6 (CN)minor, 121.5 (CN)major, 64.3
(d, 2JPC = 6.0 Hz, OCH2)minor, 64.0 (d, 2JPC = 6.0 Hz, OCH2)major, 63.3 (d, 2JPC = 6.2 Hz,
OCH2)major, 48.4 (d, 1JPC = 201.8 Hz, CH-P)major, 47.8 (d, 1JPC = 201.3 Hz, CH-P)minor, 47.5 (d,
2JPC = 3.4 Hz, Cquat)major, 46.0 (d, 2JPC = 3.00 Hz, Cquat)minor, 16.6, 16.5, 16.5, 16.4 (OCH2CH3),
12.5 (CH3)major, 12.1 (CH3)minor ppm; 31P NMR (120 MHz, CDCl3) δ 13.8major, 13.3minor ppm;
ESI-HRMS (CI) m/z calculated for C15H21N3O4P ([M + H]+) 338.1270 found 338.1254.
(E)-(4S*,5S*)-5-(Diphenylphosphoryl)-4-methyl-2-(p-tolylamino)-4,5-dihydrooxazole-4-
carbonitrile (7c) and (E)-(4S*,5S*)-4-(diphenylphosphoryl)-5-methyl-2-(p-tolylamino)-4,5-
dihydrooxazole-5-carbonitrile (7′c), (1.56 g, 75%) were obtained as white solids from
N-functionalized cyanoaziridine 5c (2.07 g, 5 mmol) as described in the general proce-
dure. The crude product was purified by flash-column chromatography (AcOEt) to give
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the title compound 7 as a mixture of two regioisomers 7c +7′c; mp 128–130 ◦C; IR (neat)
vmax 3425, 3059, 2959, 2235, 1617, 1516, 1438, 1405, 1197, 1119 cm−1; 1H NMR (400 MHz,
CDCl3) δ 8.01 (bs, 1H, NH), 7.96–7.01 (m, 29H, ArH + NH), 2.98 (d, 2JPH = 15.5 Hz, 1H, CH-
P)minor, 2.98 (d, 2JPH = 16.7 Hz, 1H, CH-P)major, 2.37 (s, 3H, CH3)major, 2.33 (s, 3H, CH3)minor,
1.80 (s, 3H, CH3)major, 1.68 (s, 3H, CH3)minor ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 166.8
(C=N)minor, 162.1 (C=N)major, 140.0 (Cquat), 138.8 (Cquat), 132.9, 132.0, 131.9, 131.3, 131.2,
131.1, 131.0, 130.4, 130.0, 129.7, 129.3, 129.2, 129.0, 128.9, 128.2, 127.5, 126.8, 126.4 (CAr),
121.5 (d, 3JPC = 3.8 Hz, CN), 51.5 (d, 1JPC = 95.9 Hz, CH-P)major, 51.6 (d, 1JPC = 95.2 Hz,
CH-P)minor, 48.8 (d, 2JPC = 3.1Hz Cquat)major, 47.1 (Cquat), 21.3 (CH3), 12.3 (CH3)major, 11.9
(CH3)minor ppm; 31P NMR (120 MHz, CDCl3) δ 21.0major, 20.8minor ppm; ESI-HRMS (CI)
m/z calculated for C24H23N3O2P ([M + H]+) 416.1528 found 416.1544.
Diethyl (E)-[(4S*,5S*)-4-cyano-4-methyl-2-(p-tolylamino)-4,5-dihydroozazol-5-yl]phosphonate
(7d) and diethyl (E)-[(4S*,5S*)-5-cyano-5-methyl-2-(p-tolylamino)-4,5-dihydroozazol-5-
yl]phosphonate (7′d), (0.95 g, 54%) were obtained as waxy white solids from N-functionalized
cyanoaziridine 5d (1.75 g, 5 mmol) as described in the general procedure. The crude product
was purified by flash-column chromatography (SiO2, AcOEt) to give the title compound 7d
+ 7′d as a mixture of two regioisomers; Rf: 0.1 (AcOEt); IR (neat) vmax 3356, 3037, 2987, 2237,
1671, 1516, 1444, 1402, 1321, 1260, 1160, 1127, 1049, 1024 cm−1; 1H NMR (300 MHz, CDCl3)
δ 8.05 (bs, 1H, NH)minor, 7.49 (bs, 1H, NH)major, 7.31–7.00 (m, 8H, ArH), 4.33–4.21 (m, 8H,
OCH2), 2.62 (d, 2JPH = 11.1 Hz, 1H, CH-P)major, 2.60 (d, 2JPH = 11.3 Hz, 1H, CH-P)minor, 2.37 (s,
3H, CH3)major, 2.33 (s, 3H, CH3)minor, 1.89 (s, 3H, CH3)major, 1.85 (s, 3H, CH3)minor, 1.41–1.33 (m,
12H, OCH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 166.7 (d, 3JPC = 3.0 Hz, C=N)minor,
162.1 (d, 1JPC = 3.7 Hz, C=N)major, 140.0 (Cquat), 138.9 (Cquat), 131.0, 130.6, 130.1, 129.7, 128.2,
126.9, 126.5 (CAr), 127.6 (CN)major, 121.3 (d, 3JPC = 5.5 Hz, CN)minor, 64.3 (d, 2JPC = 6.0 Hz,
OCH2)minor, 64.0 (d, 2JPC = 5.9 Hz, OCH2)minor, 63.3 (d, 2JPC = 6.2 Hz, OCH2)major, 48.4
(d, 1JPC = 201.8 Hz, CH-P)major, 47.9 (d, 1JPC = 201.8 Hz, CH-P)minor, 47.5 (d, 2JPC = 3.2 Hz,
Cquat)major, 46.0 (Cquat)minor, 21.3 (CH3), 16.6, 16.6, 16.5, 16.5 (OCH2CH3), 12.5 (CH3)major, 12.2
(CH3)minor ppm; 31P NMR (120 MHz, CDCl3) δ 13.9major, 13.4minor ppm; ESI-HRMS (CI) m/z
calculated for C16H23N3O4P ([M + H]+) 352.1426 found 352.1426.
General Procedure and Spectral Data for Compound 8a
To a −70 ◦C solution of 6a (5 mmol, 1 eq) in THF (25 mL) boron trifluoride diethyl
etherate (25 mmol, 5 eq) was added dropwise. The reaction mixture was stirred at −70 ◦C
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for 24 h until TLC showed the disappearance of the starting N-functionalized cyanoaziri-
dine. The crude product was washed three times with water (15 mL) and extracted with
CH2Cl2 (15 mL). The organic layers were dried over anhydrous MgSO4, filtered, and
concentrated to dryness in vacuum conditions, and the resulting residue was purified by
flash-column chromatography.
Ethyl (Z)-[(4R*,5S*)-5-cyano-4-(diphenylphosphoryl)-5-methyl-4,5-dihydrothiazol-2-yl]carbamate
(8a), (1.39 g, 67%) was obtained as a pale yellow solid from N-functionalized cyanoaziridine 6a
(2.06 g, 5 mmol) and boron trifluoride diethyl etherate (3.1 mL, 25 mmol, 5 eq) as described in
the general procedure. The crude product was purified by flash-column chromatography (SiO2,
AcOEt/hexane 50:50) to give the title compound 8a; mp 208–210 ◦C; IR (neat) vmax 3145, 3065,
2937, 2254, 2232, 1724, 1624, 1507, 1438, 1244, 1174, 1113, 1094 cm−1; 1H NMR (400 MHz, CDCl3)
δ 8.06–7.40 (m, 11H, ArH + NH), 4.58 (d, 2JPH = 12.8 Hz, 1H, CH-P), 4.22–4.16 (m, 2H, CH2),
2.11 (s, 3H, CH3), 1.25 (t, 3JHH = 7.1 Hz, 3H, CH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ
157.1 (d, 3JPC = 19.4 Hz, C=N), 152.8 (C=O), 134.0 (Cquat), 133.3, 133.2, 132.7, 132.6, 132.5, 132.4,
132.4, 131.3, 131.2, 129.2, 128.9, 128.7, 128.2, 128.1, 127.9 (CAr), 118.8 (d, 3JPC = 7.1 Hz, CN), 76.6
(d, 1JPC = 82.7 Hz, CH-P), 63.1 (CH2), 52.0 (d, 2JPC = 1.3 Hz, Cquat), 26.4 (CH3), 14.4 (CH3) ppm;
31P NMR (120 MHz, CDCl3) δ 26.1 ppm; ESI-HRMS (CI) m/z calculated for C20H21N3O3PS
([M + H]+) 414.1041 found 414.1046.
General Procedure and Spectral Data for The Reaction of Cyanoaziridines 1 and
Isocyanates in The Ppresence of KI
A mixture of the corresponding isocyanate (2 mmol, 2 eq), KI (0.25 g, 0.3 mmol) and
cyanoaziridine (1 mmol, 1 eq) in CH3CN (15 mL) was stirred at 60 ◦C until TLC showed
the disappearance of the starting cyanoaziridine. After the completion of the reaction, the
solvent was evaporated under reduced pressure and the crude product was washed three
times with water (15 mL) and extracted with CH2Cl2 (15 mL). The organic layers were dried
over anhydrous MgSO4, filtered and concentrated to dryness in vacuum conditions, and
the resulting residue was purified by crystallization or by flash-column chromatography.
(E)-(4S*,5S*)-4-Cyano-5-(diphenylphosphoryl)-4-ethyl-N-phenyl-2-(phenylimino)oxazolidine-
3-carboxamide (9a), (1.66 g, 62%) was obtained as a white solid from cyanoaziridine 5a (1.48 g,
5 mmol) and phenyl isocyanate (1.09 mL, 10 mmol, 2 eq) as described in the general procedure.
The crude product was purified by flash-column chromatography (SiO2, AcOEt/hexane 40:60)
to give the title compound 9a; mp 208–210 ◦C; IR (neat) vmax 3267, 3062, 2973, 2246, 1779, 1560,
1502, 1435, 1383, 1316, 1260, 1225, 1119 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.01–7.07 (m, 21H,
ArH + NH), 3.32 (d, 2JPH = 18.7 Hz, 1H, CH-P), 2.46–2.27 (m, 2H, CH2), 1.05 (t, 3JHH = 7.4 Hz,
3H, CH2CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 164.6 (d, 3JPC = 6.0 Hz, C=N), 157.9
(C=O), 138.0 (Cquat), 133.1, 133.0, 132.2, 132.1, 131.9, 131.8, 131.7, 129.0, 126.9, 124.2, 119.2 (CAr),
121.6 (CN), 55.1 (d, 1JPC = 96.5 Hz, CH-P), 54.5 (Cquat), 18.9 (CH2), 10.3 (CH3) ppm; 31P NMR
(120 MHz, CDCl3) δ 24.1 ppm; ESI-HRMS (CI) m/z calculated for C31H28N4O3P ([M + H]+)
535.1899 found 535.1899.
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(E)-(4S*,5S*)-4-Cyano-5-(diphenylphosphoryl)-4-methyl-N-(p-tolyl)-2-(p-tolylimino)oxazolidine-
3-carboxamide (9b), (1.51 g, 55%) was obtained as a white solid from cyanoaziridine 5c (1.41 g,
5 mmol) and p-tolyl isocyanate (1.26 mL, 10 mmol, 2 eq) as described in the general procedure.
The crude product was purified by flash-column chromatography (SiO2, AcOEt/hexane 50:50)
to give the title compound 9b; mp 220–222 ◦C; IR (neat) vmax 3259, 3040, 2926, 2246, 1777, 1613,
1596, 1513, 1438, 1391, 1241, 1172, 1191, 1155 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.03–7.01(m,
19H, ArH + NH), 3.21 (d, 2JPH = 18.2 Hz, 1H, CH-P), 2.33 (s, 3H, CH3), 2.29 (s, 3H, CH3), 1.91 (s,
3H, CH3) ppm; 13C {1H} NMR (75 MHz, CDCl3) δ 164.6 (d, 3JPC = 6.0 Hz, C=N), 158.1 (C=O),
139.4 (Cquat), 135.4 (Cquat), 133.8 (Cquat), 133.1, 132.9, 132.9, 132.0, 131.9, 131.8, 130.0, 129.7, 129.5,
129.3, 129.2, 128.9, 126.7, 120.9, 120.3, 119.2, (CAr + CN), 53.9 (d, 1JPC = 92.0 Hz, CH-P), 49.1 (d,
2JPC = 3.8 Hz, Cquat), 21.3 (CH3), 21.0 (CH3), 12.6 (CH3) ppm; 31P NMR (120 MHz, CDCl3) δ 23.7
ppm; ESI-HRMS (CI) m/z calculated for C32H30N4O3P ([M + H]+) 549.2056 found 549.2056.
Diethyl (E)-[(4S*,5S*)-4-cyano-4-methyl-3-(phenylcarbamoyl)-2-(phenylimino)oxazolidin-5-
yl]phosphonate (9c), (1.80 g, 79%) was obtained as a pale yellow solid from cyanoaziridine
1c (1.09 g, 5 mmol) and phenyl isocyanate (1.09 mL, 10 mmol, 2 eq) as described in the
general procedure. The crude product was purified by crystallization from Et2O to give
the title compound 9c; mp 169–171 ◦C; IR (neat) vmax 3231, 3140, 2985, 2249, 1716, 1610,
1580, 1499, 1488, 1313, 1249, 1194, 1052, 1024 cm−1; 1H NMR (300 MHz, CDCl3) δ 7.47–7.02
(m, 10H, ArH), 6.58 (d, 1H, NH), 4.19–4.02 (m, 4H, OCH2), 3.98 (d, 2JPH = 12.4 Hz, 1H,
CH-P), 1.98 (s, 3H, CH3), 1.24–1.16 (m, 3H, OCH2CH3) ppm; 13C {1H} NMR (75 MHz,
CDCl3) δ 177.3 (d, 2JPC = 15.9 Hz, C=N), 158.5 (C=O) 151.2 (d, 3JPC = 12.4 Hz, Cquat), 145.2
(Cquat), 134.5 (Cquat), 129.5, 129.3, 129.1, 128.6, 128.5, 127.9, 127.7, 124.4, 123.7, 123.5 (CAr),
120.1 (CN), 80.3 (d, 2JPC = 6.1 Hz, Cquat), 64.4 (d, 2JPC = 6.8 Hz, OCH2), 63.7 (d, 2JPC = 6.7 Hz,
OCH2), 52.0 (d, 1JPC = 156.6 Hz, CH-P), 19.2 (CH3), 16.3 (d, 2JPC = 5.8 Hz, OCH2CH3) ppm;
31P NMR (120 MHz, CDCl3) δ 15.1 ppm; ESI-HRMS (CI) m/z calculated for C22H26N4O5P
([M + H]+) 457.1641 found 457.1629.
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3.2. Biology
3.2.1. Materials
Reagents and solvents were used as purchased without further purification. All
stock solutions of the investigated compounds were prepared by dissolving the powered
materials in appropriate amounts of DMSO. The final concentration of DMSO never
exceeded 10% (v/v) in reactions. The stock solution was stored at 5 ◦C until it was used.
3.2.2. Cytotoxicity Assays
Cells were cultured according to the supplier’s instructions. Cells were seeded in
96-well plates at a density of 2–4 × 103 cells per well and incubated overnight in 0.1 mL
of media supplied with 10% Fetal Bovine Serum (Lonza) in a 5% CO2 incubator at 37 ◦C.
On day 2, the compounds were added, and the samples were incubated for 48 h. After
treatment, 10 µL of the cell counting kit-8 was added into each well for an additional 2 h
incubation at 37 ◦C. The absorbance of each well was determined by an Automatic Elisa
Reader System at a 450 nm wavelength.
4. Conclusions
In summary, we herein report the activation of NH-cyanoaziridines with phosphorus
substituents by N-acylation or N-carbamoylation reactions. As far as we know, this method-
ology constitutes the first example of N-functionalization of phosphorus-substituted NH-
cyanoaziridines with iso(thio)cyanates for the preparation of N-(thio)carbamoyl
cyanoaziridines derived from phosphine oxide and phosphonate. Furthermore, we ex-
amined the ring expansion reaction of synthesized cyanoaziridines for the preparation of
5-membered nitrogen-containing heterocycles. For instance, N-acylated cyanoaziridine
2a regioselectively isomerized (Heine-type reaction) to 4-cyanooxazoline 3a in the pres-
ence of NaI. However, when N-carbamoyl cyanoaziridines 5 react in the same reaction
conditions, 2-aminocyanooxazolines 7 are achieved as a mixture of regioisomers. The
Heine-type reaction of N-thiocarbamoyl cyanoaziridine 6a was performed using mild
acidic conditions (BF3·OEt2 as a Lewis acid), since neither thermal nor nucleophilic con-
ditions produced the corresponding 2-aminocyanothiazoline 8a. We also examined the
one pot reaction of cyanoaziridines 1 with isocyanates. The ring expansion reaction of
N-carbamoyl cyanoaziridines 5 in situ prepared by the reaction of cyanoaziridines 1 with
isocyanates, followed by the insertion of a second equivalent of isocyanate, obtained
2-iminocyanooxazolidines 9 in a regioselective way. Additionally, we evaluated the cyto-
toxic effect of all the synthesized compounds inhibiting the growth of the human tumor
cell lines A549 (carcinomic human alveolar basal epithelial cells). Within the N-acylated
and N-(thio)carbamoylated cyanoaziridines, only compound 2a exhibited a moderate
cytotoxic effect with an IC50 of 22.9 ± 1.9µM. Concerning the 5-membered nitrogen-
containing heterocycles, 4-cyanooxazoline 3a showed a IC50 value of 19.7 ± 2.8 µM, since
2-iminooxazolidines 9 exhibited IC50 values between 6.2 ± 0.7 and 16.4 ± 1.5 µM. In ad-
dition, the cytotoxic effect of our compounds in healthy lung cells, fibroblast lung cells
(MRC-5), seemed not to present any effect.
Supplementary Materials: The following are available online: 1H and 13C NMR spectra of synthe-
sized compounds 2, 3, 5–9.
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